Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Holdings Increased by Pacer Advisors Inc.

Pacer Advisors Inc. increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 0.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,509,609 shares of the company’s stock after purchasing an additional 14,695 shares during the quarter. Pacer Advisors Inc. owned 4.42% of Harmony Biosciences worth $75,715,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in HRMY. LSV Asset Management raised its holdings in shares of Harmony Biosciences by 346.5% in the 1st quarter. LSV Asset Management now owns 335,146 shares of the company’s stock worth $11,254,000 after purchasing an additional 260,093 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Harmony Biosciences by 53.7% in the 2nd quarter. American Century Companies Inc. now owns 681,536 shares of the company’s stock worth $20,562,000 after purchasing an additional 238,140 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Harmony Biosciences by 56.7% in the 2nd quarter. Renaissance Technologies LLC now owns 595,800 shares of the company’s stock worth $17,975,000 after purchasing an additional 215,700 shares in the last quarter. Capital Management Corp VA bought a new stake in shares of Harmony Biosciences in the 1st quarter worth approximately $7,018,000. Finally, Janus Henderson Group PLC raised its holdings in shares of Harmony Biosciences by 1,011.7% in the 1st quarter. Janus Henderson Group PLC now owns 185,083 shares of the company’s stock worth $6,214,000 after purchasing an additional 168,434 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Price Performance

HRMY opened at $39.29 on Friday. Harmony Biosciences Holdings, Inc. has a 1 year low of $18.61 and a 1 year high of $39.73. The stock has a fifty day moving average price of $35.22 and a 200 day moving average price of $32.26. The company has a current ratio of 3.13, a quick ratio of 3.09 and a debt-to-equity ratio of 0.32. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 0.75 and a beta of 0.73.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, August 6th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.24. The company had revenue of $172.80 million during the quarter, compared to the consensus estimate of $172.53 million. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. The company’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.56 earnings per share. Analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on HRMY. UBS Group began coverage on shares of Harmony Biosciences in a research report on Tuesday, September 10th. They issued a “buy” rating and a $56.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research report on Thursday, September 12th. Finally, Citigroup began coverage on shares of Harmony Biosciences in a research report on Friday, June 21st. They issued a “buy” rating and a $48.00 target price on the stock. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.